Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150495 | 0.87 | TGFBR1 (0.48) | TGFBR1CYP3A4CYP2C8TGFBR2PIM1 | |
| SCHEMBL4156960 | 0.84 | TGFBR1 (0.43) | TGFBR1CYP3A4CYP2C8TGFBR2JAK2 | |
| SCHEMBL3667334 | 0.82 | TGFBR1 (0.43) | TGFBR1CYP3A4CYP2C8TGFBR2JAK2 | |
| SCHEMBL4167789 | 0.81 | JAK1 (0.43) | TGFBR1CYP3A4CYP2C8JAK1 | |
| SCHEMBL4153898 | 0.80 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8TGFBR2CYP2A6 | |
| SCHEMBL4151363 | 0.80 | TGFBR1 (0.53) | TGFBR1CYP3A4CYP2C8TGFBR2CYP2A6 | |
| SCHEMBL3794751 | 0.79 | TGFBR1 (0.52) | TGFBR1CYP3A4CYP2C8TGFBR2JAK1 | |
| SCHEMBL4165292 | 0.79 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8TGFBR2JAK1 | |
| SCHEMBL3802774 | 0.78 | CYP3A4 (0.51) | TGFBR1CYP3A4CYP2C8TGFBR2CYP2A6 | |
| SCHEMBL4158344 | 0.78 | TGFBR1 (0.48) | TGFBR1CYP3A4CYP2C8TGFBR2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.